clinical trial · NCT07223697
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Hoffmann-La Roche·phase2·recruiting·n = 120
Atopic DermatitisAfimkibart
brief summary
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
started
Jan 8, 2026
primary completion
Feb 11, 2033
completion
Feb 11, 2033
last updated
Apr 13, 2026
official title
An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol